Preclinical research has shown efficacy of combining mTOR inhibitors with PD‐1/PD‐L1 inhibitors in syngeneic mouse models of renal cell carcinoma [40] oral cavity cancer [41], and colorectal cancer [42]. This evidence concerns the gene CD274 and oral cavity cancer.